Clinical Research Directory
Browse clinical research sites, groups, and studies.
Intravenous Labetalol vs Phentolamine for the Management of Severe Preeclampsia.
Sponsor: Assiut University
Summary
The only effective treatment of severe preeclampsia is delivery of the fetus but immediate antihypertensive treatment is given to stabilize the patient and prevent further complications. All antihypertensive medication can potentially cross the placenta. At this time, there are no randomized control trials to base a recommendation for the use of one antihypertensive agent over another. However, certain medications are effective in lowering blood pressure with an acceptable safety profile in pregnancy. The choice of therapy depends on the acuity and severity of hypertension
Official title: Intravenous Labetalol Versus Phentolamine for the Management of Severe Preeclampsia , Randomized Controlled Clinical Trial
Key Details
Gender
FEMALE
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2024-05-20
Completion Date
2026-03-20
Last Updated
2024-04-26
Healthy Volunteers
No
Conditions
Interventions
Labetalol
Group L will recieve labetalol intravenous infusion (Trandate, Gsk) in a concentration of 10 mg/ ml, thus 50 mg/ml equals to 5 ml/hr. The starting infusion rate of the antihypertensive medication is 5 ml/hr for an 80 Kg patient.
Phentolamine
Group P will receive phentolamine intravenous infusion (Rogitamine) in a concentration of 10 mg/ml, thus 1 µg/Kg/min equals to 4.8 ml/hr for an 80 Kg patient.